Agios (AGIO) | Financial Analysis & Statements
Agios Pharmaceuticals Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
20.0M
Gross Profit
18.1M
90.59%
Operating Income
-121.6M
-608.89%
Net Income
-108.0M
-541.09%
Balance Sheet Metrics
Total Assets
1.3B
Total Liabilities
104.1M
Shareholders Equity
1.2B
Debt to Equity
0.09
Cash Flow Metrics
Operating Cash Flow
-101.3M
Free Cash Flow
-97.3M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Agios Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 54.0M | 36.5M | 26.8M | 14.2M | 0 |
| Cost of Goods Sold | 6.3M | 4.2M | 2.9M | 1.7M | 0 |
| Gross Profit | 47.7M | 32.3M | 23.9M | 12.5M | 0 |
| Gross Margin % | 88.3% | 88.6% | 89.3% | 88.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 339.5M | 301.3M | 295.5M | 279.9M | 257.0M |
| Selling, General & Administrative | 180.3M | 156.8M | 119.9M | 121.7M | 121.4M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 519.8M | 458.1M | 415.4M | 401.6M | 378.4M |
| Operating Income | -472.1M | -425.7M | -391.5M | -389.0M | -378.4M |
| Operating Margin % | -873.9% | -1,166.5% | -1,459.5% | -2,732.1% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | 56.4M | 48.1M | 33.3M | 12.8M | 836.0K |
| Interest Expense | - | - | - | - | - |
| Other Non-Operating Income | 2.0M | 1.1B | 6.1M | 144.5M | 21.1M |
| Pre-tax Income | -413.8M | 718.0M | -352.1M | -231.8M | -356.5M |
| Income Tax | -1.0M | 44.2M | - | - | - |
| Effective Tax Rate % | 0.0% | 6.2% | 0.0% | 0.0% | 0.0% |
| Net Income | -412.8M | 673.7M | -352.1M | -231.8M | 1.6B |
| Net Margin % | -764.0% | 1,845.9% | -1,312.6% | -1,627.8% | 0.0% |
| Key Metrics | |||||
| EBITDA | -467.0M | -1.5B | -384.9M | -518.2M | -375.8M |
| EPS (Basic) | $-7.12 | $11.86 | $-6.33 | $-4.23 | $26.55 |
| EPS (Diluted) | $-7.12 | $11.64 | $-6.33 | $-4.23 | $26.55 |
| Basic Shares Outstanding | 57972004 | 56807415 | 55651487 | 54789435 | 60447346 |
| Diluted Shares Outstanding | 57972004 | 56807415 | 55651487 | 54789435 | 60447346 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Agios Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 89.1M | 76.2M | 88.2M | 139.3M | 203.1M |
| Short-term Investments | 765.3M | 817.5M | 688.7M | 643.9M | 816.9M |
| Accounts Receivable | 10.6M | 4.1M | 2.8M | 2.2M | 0 |
| Inventory | 32.9M | 27.6M | 19.1M | 8.5M | 0 |
| Other Current Assets | 44.1M | 40.2M | 35.0M | 39.0M | 39.8M |
| Total Current Assets | 942.1M | 965.6M | 833.8M | 832.8M | 1.1B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 17.6M | 17.5M | 17.4M | 23.2M | 22.3M |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 3.9M | 4.7M | 4.1M | 4.0M | 2.9M |
| Total Non-Current Assets | 355.2M | 697.6M | 103.3M | 405.9M | 373.5M |
| Total Assets | 1.3B | 1.7B | 937.1M | 1.2B | 1.4B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 18.4M | 16.6M | 9.8M | 18.6M | 16.7M |
| Short-term Debt | 18.4M | 16.8M | 15.0M | 13.7M | 11.2M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 82.2M | 81.2M | 68.0M | 62.6M | 59.8M |
| Non-Current Liabilities | |||||
| Long-term Debt | 21.8M | 40.2M | 57.0M | 72.0M | 85.9M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 90.0K | 880.0K | 1.2M | 3.3M | - |
| Total Non-Current Liabilities | 21.9M | 41.1M | 58.1M | 75.3M | 85.9M |
| Total Liabilities | 104.1M | 122.2M | 126.1M | 137.9M | 145.8M |
| Equity | |||||
| Common Stock | 75.0K | 73.0K | 72.0K | 71.0K | 71.0K |
| Retained Earnings | -561.7M | -148.9M | -822.6M | -470.6M | -238.8M |
| Treasury Stock | 802.5M | 802.5M | 802.5M | 802.5M | 802.5M |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 1.2B | 1.5B | 811.0M | 1.1B | 1.3B |
| Key Metrics | |||||
| Total Debt | 40.2M | 57.0M | 72.0M | 85.7M | 97.1M |
| Working Capital | 859.8M | 884.4M | 765.9M | 770.1M | 1.0B |
Balance Sheet Composition
Agios Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -412.8M | 673.7M | -352.1M | -231.8M | -356.5M |
| Depreciation & Amortization | 5.2M | 5.7M | 6.6M | 8.6M | 9.2M |
| Stock-Based Compensation | 52.6M | 42.8M | 44.8M | 49.3M | 53.5M |
| Working Capital Changes | -27.6M | -18.5M | -35.7M | -14.6M | -10.0M |
| Operating Cash Flow | -360.2M | -173.9M | -308.2M | -306.4M | -294.3M |
| Investing Activities | |||||
| Capital Expenditures | -4.3M | -1.6M | 326.0K | -3.9M | -5.7M |
| Acquisitions | 0 | 1.1B | 0 | 131.8M | - |
| Investment Purchases | -641.8M | -1.5B | -417.9M | -1.0B | -1.4B |
| Investment Sales | 1.0B | 818.4M | 674.7M | 1.1B | 829.8M |
| Investing Cash Flow | 387.2M | 363.4M | 257.1M | 375.0M | -554.2M |
| Financing Activities | |||||
| Share Repurchases | - | - | 0 | 0 | -802.5M |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | 0 | 0 | -331.0K | -578.0K |
| Financing Cash Flow | - | 0 | 0 | -331.0K | -803.1M |
| Free Cash Flow | -387.3M | -391.5M | -314.6M | -314.4M | -413.1M |
| Net Change in Cash | 27.0M | 189.5M | -51.1M | 68.3M | -1.7B |
Cash Flow Trend
Agios Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
3.82
Forward P/E
-5.26
Price to Book
1.26
Price to Sales
27.91
PEG Ratio
-5.26
Profitability Ratios
Profit Margin
88.26%
Operating Margin
-608.90%
Return on Equity
-30.20%
Return on Assets
-19.94%
Financial Health
Current Ratio
11.46
Debt to Equity
3.37
Beta
0.78
Per Share Data
EPS (TTM)
$-7.12
Book Value per Share
$20.41
Revenue per Share
$0.93
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| AGIO | 1.5B | 3.82 | 1.26 | -30.20% | 88.26% | 3.37 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Capricor | 2.0B | -15.61 | 6.62 | -46.56% | 0.00% | 4.75 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
| Amylyx | 1.9B | 2.54 | 6.31 | -61.59% | 0.00% | 1.95 |
Financial data is updated regularly. All figures are in the company's reporting currency.






